Foley Hoag Represents Genevant Sciences in Global Collaboration and License Agreement with Takeda

March 15, 2021

Foley Hoag LLP represented Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent estate, in closing a global collaboration and license agreement with Takeda Pharmaceutical Company Limited. Under the terms of the agreement, Genevant will partner with Takeda in the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis. Genevant is initially eligible to receive up to $600 million in upfront and milestone payments, plus royalties on future product sales.

Genevant has decades of experience and expertise in nucleic acid drug delivery and development. Its LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production and gene editing.

Foley Hoag attorneys Hemmie Chang and Kathryn Lumb represented Genevant in the transaction, with assistance from Areta Kupchyk and Nicola Lemay

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.